CoChat

End‐to‐end collaboration to transform biopharmaceutical development and manufacturing

Open access
Erickson, John, Baker, Jeffrey, Barrett, Shawn, Brady, Ciaran, Brower, Mark, Carbonell, Ruben, Charlebois, Tim, Coffman, Jon, Connell‐Crowley, Lisa, Coolbaugh, Michael, Fallon, Eric, Garr, Eric, Gillespie, Christopher, Hart, Roger, Haug, Allison, Nyberg, Gregg, Phillips, Michael, Pollard, David, Qadan, Maen, Ramos, Irina, Rogers, Kelley, Schaefer, Gene, Walther, Jason, Lee, Kelvin · 2021 · Biotechnology and Bioengineering
Cited by 48

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

An ambitious 10‐year collaborative program is described to invent, design, demonstrate, and support commercialization of integrated biopharmaceutical manufacturing technology intended to transform the industry. Our goal is to enable improved control, robustness, and security of supply, dramatically reduced capital and operating cost, flexibility to supply an extremely diverse and changing portfolio of products in the face of uncertainty and changing demand, and faster product development and supply chain velocity, with sustainable raw materials, components, and energy use. The program is organized into workstreams focused on end‐to‐end control strategy, equipment flexibility, next generation technology, sustainability, and a physical test bed to evaluate and demonstrate the technologies that are developed. The elements of the program are synergistic. For example, process intensification results in cost reduction as well as increased sustainability. Improved robustness leads to less inventory, which improves costs and supply chain velocity. Flexibility allows more products to be consolidated into fewer factories, reduces the need for new facilities, simplifies the acquisition of additional capacity if needed, and reduces changeover time, which improves cost and velocity. The program incorporates both drug substance and drug product manufacturing, but this paper will focus on the drug substance elements of the program.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/bit.27688

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 48

Metadata

Authors
Erickson, J., Baker, J., Barrett, S., Brady, C., Brower, M., Carbonell, R., Charlebois, T., Coffman, J., Connell‐Crowley, L., Coolbaugh, M., Fallon, E., Garr, E., Gillespie, C., Hart, R., Haug, A., Nyberg, G., Phillips, M., Pollard, D., Qadan, M., Ramos, I., Rogers, K., Schaefer, G., Walther, J., & Lee, K.
Venue
Biotechnology and Bioengineering
Publisher
Wiley
Published
2021-02-02
Volume
118
Issue
9
Pages
3302-3312
ISSN
  • 0006-3592 (ISSN-L)
  • 1097-0290
OpenAlex
W3121467547
Cited by
48
References
3
FWCI
2.35
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: End‐to‐end collaboration to transform biopharmaceutical development and manufacturing. https://app.cochat.ai/papers/10.1002/bit.27688
The paper
Erickson, J., Baker, J., Barrett, S., Brady, C., Brower, M., Carbonell, R., Charlebois, T., Coffman, J., Connell‐Crowley, L., Coolbaugh, M., Fallon, E., Garr, E., Gillespie, C., Hart, R., Haug, A., Nyberg, G., Phillips, M., Pollard, D., Qadan, M., . . . Lee, K. (2021). End‐to‐end collaboration to transform biopharmaceutical development and manufacturing. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.27688

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.